Top

American Journal of Clinical Dermatology

Published in:

01-06-2018 | short communication

The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study

Authors: Joyce H. Park, Amanda Bienenfeld, Seth J. Orlow, Arielle R. Nagler

Published in: American Journal of Clinical Dermatology | Issue 3/2018

Abstract

Background

Little is known about how dermatologists prescribe hormonal antiandrogen acne treatment (HAAT).

Objective

The aim of this study was to investigate dermatologists’ HAAT-prescribing habits and HAAT’s impact on systemic antibiotic use in women with acne.

Methods

We performed a retrospective study at an academic medical center of female patients receiving HAAT (combined oral contraceptive [COC], spironolactone) for acne from January 2005 to October 2015. Data from a control group of female acne patients who never received HAAT were also collected.

Results

A total of 672 female patients received HAAT. Out of all systemic medications for acne, antibiotics were used as first-line treatment in 39% of patients, COCs in 12%, and spironolactone in 21%. Mean antibiotic durations in patients who initiated HAAT for the first time at the study site (250.4 days) were significantly longer than in patients who received HAAT prior to presentation and continued HAAT at the study site (192.0 days) (p = 0.021). A statistically significant inverse association was found between HAAT use and mean antibiotic duration (p = 0.016).

Conclusions

HAAT is not typically used as a first-line systemic therapy in women with acne. HAAT usage is associated with shorter cumulative antibiotic durations and early HAAT initiation can decrease systemic antibiotic use in acne treatment.

Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56–9.CrossRefPubMed

Dreno B. The changing faces of acne. Br J Dermatol. 2015;172(Suppl 1):1–2.CrossRefPubMed

Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol JEADV. 2001;15(6):541–5.CrossRefPubMed

Barros B, Thiboutot D. Hormonal therapies for acne. Clin Dermatol. 2017;35(2):168–72.CrossRefPubMed

Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21(4):363–92.CrossRefPubMed

Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15(6):479–88.CrossRefPubMed

Dreno B, Layton A, Zouboulis CC, Lopez-Estebaranz JL, Zalewska-Janowska A, Bagatin E, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol JEADV. 2013;27(9):1063–70.CrossRefPubMed

Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg. 2001;20(3):144–53.CrossRefPubMed

Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22(5):419–28.CrossRefPubMed

10.

Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol JEADV. 2001;15(Suppl 3):57–61.CrossRefPubMed

11.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945e33–973e33.CrossRef

12.

Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;(6):CD004425.

13.

Arrington EA, Patel NS, Gerancher K, Feldman SR. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis. 2012;90(2):83–90.PubMed

14.

Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015;172(Suppl 1):37–46.CrossRefPubMed

15.

Boisselle A, Dionne FT, Tremblay RR. Interaction of spironolactone with rat skin androgen receptor. Can J Biochem. 1979;57(7):1042–6.CrossRefPubMed

16.

Harper JC. Should dermatologists prescribe hormonal contraceptives for acne? Dermatol Ther. 2009;22(5):452–7.CrossRefPubMed

17.

Tan JK, Ediriweera C. Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne. Int J Womens Health. 2010;1:213–21.PubMedPubMedCentral

18.

Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Acad Dermatol. 2014;71(3):450–9.CrossRefPubMed

19.

Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111(2):209–14.CrossRefPubMed

20.

Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115(2):227–32.CrossRefPubMed

21.

Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009;15(2):CD000194.

22.

Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;2:169–91.CrossRef

23.

Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol JEADV. 2016;30(9):1480–90.CrossRefPubMed

24.

Nast A, Dreno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, et al. European evidence-based (S3) guideline for the treatment of acne-update 2016-short version. J Eur Acad Dermatol Venereol JEADV. 2016;30(8):1261–8.CrossRefPubMed

25.

Barbieri JS, James WD, Margolis DJ. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: a retrospective analysis, 2004–2013. J Am Acad Dermatol. 2017;77(3):456e4–463e4.CrossRef

26.

Thiboutot DM, Dreno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2017;78(2S1):S1–23.e1.PubMed

27.

Neuhaus CP, Nagler AR, Orlow SJ. Teens, acne, and oral contraceptive pills: the need for greater clarity on when teens can consent. JAMA Dermatol. 2017;153(4):249–50.CrossRefPubMed

28.

George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008;27(3):188–96.CrossRefPubMed

29.

Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–37.CrossRefPubMed

30.

Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol JEADV. 2012;26(Suppl 1):1–29.CrossRefPubMed

31.

Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391–9.PubMed

32.

Dreno B, Thiboutot D, Gollnick H, Bettoli V, Kang S, Leyden JJ, et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol. 2014;24(3):330–4.PubMed

33.

Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–50.CrossRefPubMed

34.

Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol. 2014;71(1):70–6.CrossRefPubMed

35.

Nagler AR, Milam EC, Orlow SJ. The use of oral antibiotics before isotretinoin therapy in patients with acne. J Am Acad Dermatol. 2016;74(2):273–9.CrossRefPubMed

Title: The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study
Authors: Joyce H. Park
Amanda Bienenfeld
Seth J. Orlow
Arielle R. Nagler
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 3/2018
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-018-0349-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups

The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis

Management of Itch in Atopic Dermatitis

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Tildrakizumab-asmn: What’s in a Name?